Financial Data and Key Metrics Changes - Company reported record revenue of $19.1 million, up 33% year-over-year, with gross margins improving by 870 basis points to 61.6% [5][13] - Adjusted EBITDA doubled to $4.5 million, a 102% increase from the same quarter last year, and net income nearly doubled to $1.4 million, up 99% year-over-year [5][15] - Total operating expenses increased by 38.3% to $10.3 million, with SG&A rising 35.4% to $7.2 million [14] Business Line Data and Key Metrics Changes - Patient affordability business revenue grew 190% year-over-year to $7.75 million, accounting for 40.6% of total revenue, up from 18.7% in the same period last year [5][14] - Plasma compensation business revenue was $10.7 million, down 4.7% year-over-year but up 14.2% sequentially [7][8] Market Data and Key Metrics Changes - Company ended the quarter with 607 plasma centers, having onboarded 123 of the 132 awarded centers, achieving approximately 50% market share [8][9] - The company expects to onboard an additional 10 to 13 centers in the second half of the year [8] Company Strategy and Development Direction - Company plans to open a new patient services contact center to increase support capacity fourfold, addressing growing demand [6] - Introduction of a software as a service engagement platform at the International Plasma Protein Congress, indicating a shift towards becoming a broader technology provider [10] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the business prospects for the remainder of the year and into 2026, despite headwinds in the plasma business [12][17] - The company anticipates a return to organic growth in plasma collection starting in 2026 as the collection cycle improves [9] Other Important Information - Company raised its revenue guidance for 2025 to a range of $76.5 million to $78.5 million, reflecting year-over-year growth of 32.7% at the midpoint [17] - Expects net income for the year to be between $6 million and $7 million, or $0.10 to $0.12 per diluted share [18] Q&A Session Summary Question: Can you touch on the 30 to 40 programs expected to onboard in pharma? - Response indicated a mix of new clients and additional programs from existing clients, approximately fifty-fifty [22][23] Question: On the plasma side, does the expected addition of centers include the nine onboarded after June 30? - Response confirmed that it includes the nine centers [25] Question: Update on the donor management system timeline? - Response indicated targeting approval by the end of the year [26][28] Question: How does the average revenue of new centers compare to existing business? - Response stated that new centers are expected to be in line with existing averages [33] Question: What strategies are in place to retain donors from closing centers? - Response explained that donors will be directed to nearby centers, ensuring retention [35][36] Question: Breakdown of revenue within pharma? - Response clarified that revenue comes from program setup fees, monthly management fees, and various transactional fees [39][40] Question: Should the increase in revenue per pharma program be interpreted as a shift towards more specialty programs? - Response indicated that while there is a concentration on specialty products, the increase is also due to additional services offered [48][49]